1. Introduction {#j_med-2020-0030_s_001}
===============

Thrombotic microangiopathy (TMA) is defined as microangiopathic anemia, thrombocytopenia and microvascular ischemia affecting various organs. Among *Streptococcus pneumoniae (S. pneumoniae)* diseases, invasive pneumococcal diseases cause *S. pneumoniae*-associated TMA (pTMA). Most cases of pTMA occur in neonates and children aged less than 2 years old, and adult cases are remarkably rare \[[@j_med-2020-0030_ref_001]\]. We herein report a case of pTMA in an adult patient with a literature review.

2. Case {#j_med-2020-0030_s_002}
=======

A 62-year-old male with scleroderma, rheumatoid arthritis, diabetes mellitus and hypertension was taking 5mg/day of prednisolone and 8mg/week of methotrexate. The patient had originally been prescribed 20mg/day of prednisolone and the dosage was tapered to 5 mg/day 11 months previously. The patient had started to take methotrexate 10 days previously. Then, the patient complained of diarrhea, vomiting and chills. He was admitted to the previous hospital with the diagnosis of infectious enteritis and was treated with ceftriaxone. Two days later, he was transferred to the emergency room of our hospital for investigation and treatment of renal dysfunction and thrombocytopenia.

In our emergency room, the patient was alert. His body temperature was 36.9°C, heart rate 89/min, blood pressure 148/85 mmHg, SpO~2~ 99 % (ambient air), and respiratory rate 9/min. He had facial edema. Laboratory evaluation on admission revealed thrombocytopenia, elevated white blood cell count, elevated C-reactive protein level, abnormality of the coagulation-fibrinolytic system, and hepatorenal dysfunction ([Table 1](#j_med-2020-0030_tab_001){ref-type="table"}). Chest roentgenogram and thoracoabdominal contrast-enhanced computed tomography (CT) revealed no evidence of infection ([Fig. 1a-c](#j_med-2020-0030_fig_001){ref-type="fig"}). There was no splenomegaly nor atrophy of the spleen on CT ([Fig. 1d](#j_med-2020-0030_fig_001){ref-type="fig"}).

###### 

Laboratory Data

  Laboratory Data on Admission                                                               
  ---------------------------------------------------- -------- ----------- ------- -------- -------
  WBC                                                  16,7     /μL         CRP     25.62    mg/dL
  (Neu 95.5%, Eos 0.0%, Bas 0.1%, Mo 0.9%, Lym 3.5%)   TP       5-Aug       g/dL             
  Hb                                                   13.0     g/dL        Alb     3.0      g/dL
  Plt                                                  2-Apr    ×10^4^/μL   AST     329      IU/L
                                                                            ALT     156      IU/L
  Blood Coagulation                                                         ALP     412      IU/L
  FDP                                                  800      μg/mL       LDH     1678     IU/L
  D-dimer                                              344.1    μg/mL       γ-GTP   92       IU/L
  PT ratio                                             Jan-59               T-Bil   2-Sep    mg/dL
  Fibrinogen                                           145      mg/dL       BUN     50       mg/dL
                                                                            Cr      Mar-73   mg/dL
                                                                            Na      136      mEq/L
                                                                            K       5-Mar    mEq/L
                                                                            Cl      98       mEq/L
                                                                            BS      189      mg/dl

  Laboratory Data on Day 2   Laboratory Data on Day 4                                 
  -------------------------- -------------------------- ------- ------------- ------- -------
  CH-50                      45.6                       U/min   T-Bil         1-Jun   mg/dL
                                                                D-Bil         0.2     mg/dL
                                                                Haptoglobin   \<6.6   mg/dL

Alb, Serum albumin; ALP, Alkaline phosphatase; ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; Bas, Basophils; BS, Fasting blood glucose; BUN, Blood urea nitrogen; CH-50, 50% hemolytic complement activity; Cl, Serum chloride; Cr, Serum creatinine; CRP, C-reactive protein; D-Bil, Serum direct bilirubin; Eos, Eosinophils; FDP, Fibrin degradation product; Hb, Hemoglobin; K, Serum potassium; LDH, Lactate dehydrogenase; Lym, Lymphocytes; Mo, Monocytes; Na, Serum sodium; Neu, Neutrophils; Plt, Platelet count; PT, Prothrombin time; T-Bil, Serum total bilirubin; TP, Total protein; WBC, White blood cell count; γ-GTP, γ-glutamyl transpeptidase

![(a) Chest roentgenogram on arrival at our hospital showed no abnormal findings. (b) Chest computed tomography (CT) on arrival showed no abnormal findings. (c) Abdominal CT on arrival showed no abnormal findings. (d) Abdominal CT on arrival showed neither splenomegaly nor atrophy of the spleen.](med-15-204-g001){#j_med-2020-0030_fig_001}

We considered that he had disseminated intravascular coagulation (DIC) based on an infectious disease, and he was moved to the intensive care unit (ICU). His clinical course is shown in [Fig. 2](#j_med-2020-0030_fig_002){ref-type="fig"}. Continuous hemodiafiltration (CHDF) was started for renal dysfunction on the 1^st^ hospital day. On the 3rd hospital day, his hemoglobin level and platelet count decreased to 10g/dl and 3,000/μl, respectively ([Fig. 2](#j_med-2020-0030_fig_002){ref-type="fig"}), and crushed erythrocytes were found in the peripheral blood smear performed on the 5th hospital day ([Fig. 3](#j_med-2020-0030_fig_003){ref-type="fig"}). Differential diagnoses included TMA, hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP) based on his thrombocytopenia, crushed erythrocytes and renal dysfunction, and plasma exchange (PE) was performed. TTP was ruled out among the differential diagnoses because his ADAMTS13 activity was 60.3% and his ADAMTS 13 inhibitor was under 0.5. On the 5th hospital day, *S. pneumoniae* was detected in his blood culture performed at the previous hospital; therefore, we made the final diagnosis of pTMA. We stopped PE and changed the antibiotic from meropenem to ampicillin. The antibiogram of the *Streptococcus pneumoniae* performed at the previous hospital is shown in [Table 2](#j_med-2020-0030_tab_002){ref-type="table"}. The *Streptococcus pneumoniae* did not have penicillin resistance. We initially considered treating the patient with benzylpenicillin potassium (PCG). However, because the patient had renal damage and hyperkalemia, we chose to treat the patient with ampicillin.

![Our patient's clinical course. Crushed erythrocytes were found in the peripheral blood smear performed at the previons hospital, on the 5th hospital day. ABPC: ampicillin; CHDF: continuous hemodiafiltration; Cr: creatinine; Hb: hemoglobin; HD: hemodialysis; MEPM: meropenem; PC: platelet concentrate; Plt: platelet count; PE: plasma exchange.](med-15-204-g002){#j_med-2020-0030_fig_002}

![Crushed erythrocytes (arrow) in a peripheral blood smear stained with May-Giemsa stain (x1000).](med-15-204-g003){#j_med-2020-0030_fig_003}

###### 

Antibiogram of the *Streptococcus pneumoniae* isolated from our patient

  Antibiotic   MIC~50~(μg/mL)   Susceptibility
  ------------ ---------------- ----------------
  PCG          0.06             S
  AMPC         \-               S
  CVA/AMPC     \-               S
  CTX          ≤0.06            S
  CTM          ≤0.25            S
  CFPN-PI      \-               S
  CTDR-PI      \-               S
  PAPM/BP      ≤0.12            S
  MEPM         ≤0.12            S
  EM           ≥2               R
  CAM          \-               R
  CLDM         \-               S
  TC           \-               R
  VCM          ≤0.25            S
  TFLX         \-               S
  LVFX         \-               S

AMPC, amoxicillin; CAM, clarithromycin; CFPN-PI, cefcapene pivoxil; CLDM, clindamycin; CTDR-PI, cefditoren pivoxil; CTM, cefotiam; CTX, cefotaxime; CVA/AMPZ, clavulanate/amoxicillin; EM, erythromycin; LVFX, levofloxacin; MEPM, meropenem; MIC, minimum inhibitory concentration; TC, tetracycline; TFLX, tosufloxacin; PAPM/BP, panipenem/ betamipron, PCG, benzylpenicillin potassium; VCM, vancomycin

The patient's hemodynamics became stable and CHDF was switched to hemodialysis (HD) on the 8th hospital day. His condition gradually improved. He was transferred from the ICU to the normal ward on the 13th hospital day, and HD was discontinued on the 17th hospital day. He was discharged from our hospital on the 45th hospital day.

Informed consent has been obtained from patient included in this study.

3. Discussion {#j_med-2020-0030_s_003}
=============

The Japanese Clinical Guide of Atypical Hemolytic Uremic Syndrome (aHUS) published by the Japanese Society of Nephrology and the Japan Pediatric Society (JSN/JPS) \[[@j_med-2020-0030_ref_002]\] and the "Kidney Disease: Improving Global Outcomes (KDIGO)" Controversies Conference reported a consensus of classification of TMAs \[[@j_med-2020-0030_ref_003]\] ([Fig. 4](#j_med-2020-0030_fig_004){ref-type="fig"}). In the Japanese Clinical Guide, aHUS was defined as complement-mediated HUS after the exclusion of Shiga toxin-producing *Escherichia coli* (STEC)-HUS, TTP and secondary TMAs \[[@j_med-2020-0030_ref_002]\]. At the KDIGO Controversies Conference, TMA and all secondary TMAs were again classified under aHUS; however, even if TMAs are categorized as aHUS, it does not necessarily mean that all of these diseases are congenital or acquired complement-mediated HUS \[[@j_med-2020-0030_ref_003]\]. pTMA is secondary to TMA caused by infection. Sometimes differential diagnosis of TMA among secondary TMAs including HELLP syndrome is difficult, and complement-mediated HUS patients have been reported \[[@j_med-2020-0030_ref_004]\].

![Comparison of the classification of TMAs. In the classification of JSN/JPS, a genetic or complement abnormality can be found and the differentiation between atypical hemolytic uremic syndrome (aHUS) and secondary TMAs is sometimes difficult. Patients with true aHUS (i.e., complement-mediated aHUS) are sometimes diagnosed as having secondary TMA. In the classification of KDIGO, the differentiation between primary aHUS and other aHUSs, such as pregnancy, transplant are sometimes difficult. Patients with primary aHUS are sometimes diagnosed as having another type of aHUS \[[@j_med-2020-0030_ref_004]\].\
JSN/JPS, Japanese Society of Nephrology and the Japan Pediatric Society; TMA, Thrombotic microangiopathy; aHUS, atypical hemolytic uremic syndrome; HUS, hemolytic uremic syndrome; TTP, thrombotic thrombocytopenic purpura; KDIGO, Kidney Disease Improving Global Outcomes.](med-15-204-g004){#j_med-2020-0030_fig_004}

In our patient, we finally obtained the diagnosis of TMA because he had microangiopathic anemia, thrombocytopenia and microvascular ischemia affecting various organs. We initially suspected that the crushed erythrocytes were produced by plasma exchange and CHDF, but this was ruled out because crushed erythrocytes were found in the specimen obtained at the previous hospital. We assessed that he did not suffer from TTP because his ADAMTS13 activity was normal and ADAMTS13 inhibitor was not increased. *S. pneumoniae* was detected in the blood culture at the previous hospital; therefore, we concluded that he suffered from pTMA. The patient had begun living together with his 4-year-old grandchild since one month before the onset of pTMA. Although the grandchild had received pneumococcal vaccination, the grandchild may have been the infection route.

Pneumococcal infectious diseases, particularly invasive pneumococcal diseases, can cause pTMA. Invasive pneumococcal disease is defined as severe pneumococcal disease causing meningitis, bacteremia, sepsis or thoracic empyema. Although pneumococcal disease is common in both children and adults, pTMA usually occurs in children \[5,6\]. There is a possibility that splenectomy and immunosuppression are associated with pTMA in adults \[[@j_med-2020-0030_ref_006]\]. Our patient was immunosuppressed with prednisolone and methotrexate, and there is a possibility that immunosuppression caused pTMA.

In our case, antibiotics and temporary hemodialysis improved his renal function. Infection can cause complement-related aHUS, and mutation of a gene encoding a regulatory protein in the complement system can be related to the prognosis of patients with complement-related aHUS \[[@j_med-2020-0030_ref_007]\]. However, in our case, he had no mutation of the genes encoding proteins in the complement system. On the other hand, all of the gene mutations and complement abnormality of complement-related aHUS are not clear \[[@j_med-2020-0030_ref_007]\], and it is possible that genetic mutation of an unknown gene or abnormality of complement participated in the etiology and prognosis of the present case.

Endothelial injury activates a microangiopathic cascade of thrombotic vascular injury and leads to TMA \[[@j_med-2020-0030_ref_005]\]. In pTMA, *S. pneumoniae* cleaves N-acetylneuraminic acid and exposes the Thomsen--Friedenreich antigen (T-antigen) on glomerular endothelial cell glycoproteins \[[@j_med-2020-0030_ref_008]\]. This process leads to IgM binding from circulating anti-T IgM antibodies, and the clinical syndrome of TMA \[[@j_med-2020-0030_ref_009]\].

Medical treatment of pTMA consists of administration of antibiotics against *Streptococcus pneumoniae* and symptomatic care. If necessary, transfusion of washed blood products is preferable to avoid increasing the levels of preformed anti-T antibodies, whose levels are high in unwashed products \[1,9\]. PE with 5% albumin replacement fluid has been advocated for the treatment of pTMA due to the theoretical benefit of removing anti-T IgM antibodies and bacterial neuraminidase. On the other hand, previous reports indicated that PE with fresh frozen plasma was not recommended for the treatment of pTMA because preformed anti-T antibodies in the pooled product were said to worsen the condition of patients with pTMA \[1,9\]. In addition, the effect of PE in adult pTMA cases is uncertain. Maki et al. \[[@j_med-2020-0030_ref_006]\] reviewed five adult pTMA cases in the literature \[6, 10-13\]. We summarize the clinical features of the 10 reported cases and the present case in [Table 3](#j_med-2020-0030_tab_003){ref-type="table"}. PE was performed in 8 patients and HD was performed in 7 patients. Renal function recovered in 9 cases including the present case. One patient finally underwent renal transplantation even though PE and HD were performed. Another patient finally died even though antibiotic therapy and PE were performed. Accumulation of additional cases is necessary to clarify the effect of PE in adult pTMA patients.

###### 

Cases of pTMA in adult patients

  Authors                                          Age (yr)   Sex   Underlying factor                            SP infection                        Antibiotics     PE   HD   Renal outcome
  ------------------------------------------------ ---------- ----- -------------------------------------------- ----------------------------------- --------------- ---- ---- -----------------------
  von Eyben et al.\[[@j_med-2020-0030_ref_010]\]   35         M     Post-splenectomy                             Sepsis                              PC              \-   \+   Improved
  Myers et al.\[[@j_med-2020-0030_ref_011]\]       50         F     None                                         Sepsis                              ABPC+GM         \+   \+   Renal transplantation
  Ohlmann et al.\[[@j_med-2020-0030_ref_012]\]     52         F     None                                         Sepsis                              CTRX            \+   \+   Improved
  Reynolds et al.\[[@j_med-2020-0030_ref_013]\]    41         F     None                                         Pneumonia                           CTRX            \+   \+   Improved
  Maki et al.\[[@j_med-2020-0030_ref_006]\]        62         F     Post-splenectomy                             Upper tract infection respiratory   MINO            \-   \-   Improved
  Allen et al.\[[@j_med-2020-0030_ref_014]\]       83         F     None                                         Sepsis                              CAM +CVA/AMPC   \+   \+   Improved
  Saraceni et al.\[[@j_med-2020-0030_ref_015]\]    46         F     Post-splenectomy                             Sepsis                              CTRX            \-   \-   Improved
  Yang et al.\[[@j_med-2020-0030_ref_016]\]        50         M     None                                         Sepsis                              CTRX+VCM        \+   \-   Improved
  Ishiguro et al.\[[@j_med-2020-0030_ref_017]\]    65         M     chronic pulmonary obstructive disease        Sepsis                              CFPM+AZM        \+   \-   Died
  Jeante et al.\[[@j_med-2020-0030_ref_018]\]      53         M     type and alcohol 2 diabetes abuse mellitus   Pneumonia                           CTRX+LVFX       \+   \+   Improved
  Present case                                     62         M     oral immunosuppressant                       Sepsis                              MEPM+ABPC       \+   \+   Improved

We experienced a successfully treated adult pTMA case. The occurrence of pTMA is rare; therefore, further cases are necessary to clarify useful treatments for adult pTMA patients.
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aHUS

:   hemolytic uremic syndrome

CHDF

:   continuous hemodiafiltration

DIC

:   disseminated intravascular coagulation

HD

:   hemodialysis

HUS

:   hemolytic uremic syndrome

JSN/JPS

:   Japanese Society of Nephrology and the Japan Pediatric Society

KDIGO

:   Kidney Disease: Improving Global Outcomes

PE

:   plasma exchange

pTMA

:   *Streptococcus pneumoniae*-associated thrombotic microangiopathy

STEC

:   Shiga toxin-producing *Escherichia coli*

TMA

:   thrombotic microangiopathy

TTP

:   thrombotic thrombocytopenic purpura
